Innovative Clinical Outcome Assessment (COA) Solutions for Obesity Trials: Measuring Matters

Learn how IQVIA brings together key thought leaders and world-renowned experts in obesity clinical trials, offering end-to-end expertise to accelerate your trials and bring treatments to patients sooner.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/obesity-trials

Event overview:

IQVIA brings together key thought leaders and world-renowned experts in obesity clinical trials, offering end-to-end expertise to accelerate your trials and bring treatments to patients sooner. Unlike other CROs, IQVIA not only coauthored and developed the SF-36 V2, but also boasts the original authors of many widely used measures in clinical research, such as the SF-6D, and TSQM. The company’s clinical outcome assessment (COA) solutions allow for more economically sound and efficient trials. IQVIA can seamlessly capture data directly from patients’ devices, ensuring it is clean and user-friendly—a process that requires less clinical monitoring, time, and support from your site to maximize efficiency and quality.

Key take-aways

• Understand IQVIA’s unique position in identifying and measuring domains to achieve differentiating end points and how this expertise translates into superior clinical trial strategies.
  
• Explore the strategic and operational benefits of using fit-for-purpose COA measures as secondary end points to support labeling claims, making trials faster, more economically sound, and of higher quality.
  
• Learn how IQVIA’s electronic data capture solutions streamline clinical trials by enhancing precision and speed, including live monitoring of patient-reported outcomes, simplifying the process.
  
• How IQVIA’s connected devices can help gather digital end points.
  
• How to build a strategy to measure meaningful change with obesity-induced comorbidities.

Speakers:

Erica Caveney, MD
Head of Obesity, Cardiovascular, Endocrine, Renal, and Reproductive Health Centers of Excellence
IQVIA

Erica Caveney, MD, leads IQVIA’s Obesity, Cardiovascular, Endocrine, Renal, and Reproductive Health Centers of Excellence. Each center consists of physicians, scientists, and senior operational experts experienced in all aspects of diabetes drug development strategy and implementation. Each has a cross-functional team of experts concentrated on the key areas of drug development: bringing together the wealth of global expertise and experience in product development planning; data-driven trial strategy and design; and predictable high-quality trial execution to reduce study cycle times, optimize costs, and increase the probability of trial success.

Additionally, Caveney is board certified in endocrinology, diabetes, and metabolism and in internal medicine. She has served as global medical adviser for multiple phase 2 to 4 diabetes (both T1 and T2), obesity, and hypertension studies. She has authored many peer-reviewed articles and webinars on diabetes and obesity.

Elan Josielewski
Senior Director, Patient Centered Solutions and General Manager, IQVIA Quality Metric
IQVIA

Elan Josielewski is a senior director and general manager of IQVIA Quality Metric, leading the oversight of IQVIA clinical outcome assessment (COA), intellectual property, new instrument development, and license-linked services critical in implementing COAs into health research. Prior to joining IQVIA, Josielewski was the VP of patient-centered sciences at ICON; responsible for the integration of: Oxford Outcomes, Mapi Patient Centered Sciences, Mapi Language Services, and the Mapi Research Trust. Prior to joining ICON, Josielewski was the executive VP of corporate development and marketing at Mapi Group, as well as vice chairman of the Mapi Research Trust.

Josielewski has over 30 years of business leadership in life sciences, and is nearing a quarter century of specific COA experience across entire clinical and postapproval drug and device lifecycles, including phases 1 to 4 to commercialization CRO services at PharmaNet, central labs (MDS Central Labs), clinical and specimen logistics (Marken), cold chain, electronic data capture (EDC), eCOA (CRF Health), eConsent, clinical outcome assessment, and real-world evidence (Mapi).

Anthony Mikulaschek
Vice President of Commercialization for the Patient Suite at IQVIA
IQVIA

As vice president of commercialization for the patient suite at IQVIA, Anthony Mikulaschek is responsible for the commercialization of IQVIA’s eCOA, eConsent, and IRT platforms. This includes pricing and sales strategies, opportunity configuration, market needs review, IQVIA technology market placement, and strategy. Mikulaschek has extensive experience in validated system configuration, implementation, systems integration, business process reengineering, IT operations, and consulting. He has successfully led the development, delivery, and management of technology solutions for over 37 years, including 29 years in the pharmaceutical sector.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/obesity-trials